IL-36 alpha/IL-1F6 Antibody [Unconjugated]

• Reactivity: Mu
• Applications: WB, ELISA, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-36 alpha/IL-1F6 Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant mouse IL‑36 alpha /IL‑1F6
  Met1-His160
  Accession # Q9JLA2
• Specificity: Detects mouse IL‑36 alpha /IL‑1F6 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 5% cross‑reactivity with recombinant human (rh) IL-1F5, rhIL-1F6, and rhIL-1F9 is observed, and less than 2% cross-reactivity with recombinant mouse IL‑1F8, rhIL-1F7, rhIL-1 alpha , rhIL-1 beta , rhIL-1ra, and rhIL-18 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: IL36A
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Blockade of Receptor-ligand Interaction 40 ug/mL
  • ELISA
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-36 alpha/IL-1F6 Antibody [Unconjugated]

• FIL1 epsilon
• FIL1
• FIL1(EPSILON)
• FIL1E
• IL-1 epsilon
• IL1(EPSILON)
• IL1E
• IL-1E
• IL-1F6 (FIL-1-epsilon)
• IL1F6
• IL-1F6
• IL36 alpha
• IL-36 alpha
• IL36A
• interleukin 1 family, member 6 (epsilon)
• interleukin 1, epsilon
• Interleukin 36, Alpha
• Interleukin-1 epsilon
• interleukin-1 family member 6
• Interleukin-36 Alpha

Background

Mouse interleukin-36 alpha [IL-36 alpha ; also named interleukin 1 family member 6, IL-1F6 and FIL-1 epsilon (epsilon)] is a member of the IL-1 family of proteins (1‑3). IL-1 family members include IL-1 beta , IL‑1 alpha , IL-1ra, IL-18 and IL-1F5 through F10 (4). All family members show a 12 beta -strand, beta -trefoil configuration, and all family members are believed to have arisen from a common ancestral gene that has undergone multiple duplications (4). IL-1F6 is synthesized as a 160 amino acid (aa) protein that contains no signal sequence, no prosegment and no potential N-linked glycosylation site(s) (2, 5). It appears to be actively secreted (1). When found in cell lysates, it presents as an 18 kDa monomer (2). Mouse to human, full length IL-1F6 has 54% aa identity. Within the family, IL-1F6 is 29% aa identical to IL-1ra, and 32%, 32%, 34%, 41%, and 28% aa identical to IL-1 beta , IL-1F5, F8, F9, and F10, respectively. Cells reported to express IL-1F6 include monocytes, B cells and T cells (1, 4). Notably, IL-1F6 is the only novel IL-1 family member found to be expressed on T-cells. The receptor for IL-1F6 is reported to be a combination of IL-1 Rrp2 and IL-1 RAcP (6). Recombinant IL‑1F6, along with IL-1F8 and IL-1F9, has been shown to act as an agonist by activating the pathway involving NF-kappa B and MAPK in an IL-1 Rrp2 dependent manner. This suggests that IL‑1F6 may signal in similar fashion to IL-1 and IL-18 in having a binding receptor which upon ligation, recruits a second receptor as a signaling component, forming an active heterodimeric receptor complex.

1. Smith, D.E. et al. (2000) J. Biol. Chem. 275:1169.
2. Kumar, S. et al. (2000) J. Biol. Chem. 275:10308.
3. Nicklin, M.J.H. et al. (2002) Genomics. 79:718.
4. Dunn, E. et al. (2001) Trends Immunol. 22:533.
5. Debets, R. et al. (2001) J. Immunol. 167:1440.
6. Towne, J.E. et al. (2004) J. Biol. Chem. 279:13677.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-36 alpha/IL-1F6 Antibody (AF2297)(13)

Publications using AF2297

• CG Pelcastre-, EA Vazquez-Sa, JM Murrieta-C, S Rodríguez-, JC Cancino-Di, ME Cancino-Di MES SV40 Cells Are Sensitive to Lipopolysaccharide, Peptidoglycan, and Poly I:C Expressing IL-36 Cytokines International Journal of Molecular Sciences, 2022-10-07;23(19):. 2022-10-07 [PMID: 36233224] (ICC, Western Blot, Mouse)
• Drake Winslow Williams, Reuben H. Kim Epithelial cells release IL-36 alpha in extracellular vesicles following mechanical damage Biochemical and Biophysical Research Communications 2022-05-01 [PMID: 35316764]
• J El-Awaisi, DP Kavanagh, MR Rink, CJ Weston, NE Drury, N Kalia Targeting IL-36 improves age-related coronary microcirculatory dysfunction and attenuates myocardial ischaemia-reperfusion injury in mice JCI Insight, 2022-03-08;0(0):. 2022-03-08 [PMID: 35113814] (IHC, Mouse)
• Xiaofang Wang, Yuejin Liang, Hui Wang, Biao Zhang, Lynn Soong, Jiyang Cai et al. The Protective Role of IL-36/IL-36R Signal in Con A–Induced Acute Hepatitis The Journal of Immunology 2022-02-15 [PMID: 35046104]
• A Nerlich, N Janze, R Goethe Analysis of Il36a induction by C/EBPbeta via a half-CRE�C/EBP element in murine macrophages in dependence of its CpG methylation level Genes and immunity, 2021-10-25;0(0):. 2021-10-25 [PMID: 34697411] (Western Blot, Mouse)
• B Germán, R Wei, P Hener, C Martins, T Ye, C Gottwick, J Yang, J Seneschal, K Boniface, M Li Disrupting the IL-36 and IL-23/IL-17 loop underlies the efficacy of calcipotriol and corticosteroid therapy for psoriasis JCI Insight, 2019-01-24;4(2):. 2019-01-24 [PMID: 30674716] (IHC, Mouse)
• Seitaro Nakagawa, Masanori Matsumoto, Yuki Katayama, Rena Oguma, Seiichiro Wakabayashi, Tyler Nygaard et al. Staphylococcus aureus Virulent PSM alpha Peptides Induce Keratinocyte Alarmin Release to Orchestrate IL-17-Dependent Skin Inflammation Cell Host & Microbe 2017-11-08 [PMID: 29120744]
• MA Masum, O Ichii, YHA Elewa, T Nakamura, Y Kon Local CD34-positive capillaries decrease in mouse models of kidney disease associating with the severity of glomerular and tubulointerstitial lesions BMC Nephrol, 2017-09-04;18(1):280. 2017-09-04 [PMID: 28870174] (IHC-P, Mouse)
• V Schmitt, M Hahn, V Kästele, O Wagner, M Wiendl, A Derer, A Taddeo, S Hahne, A Radbruch, HM Jäck, W Schuh, D Mielenz, S Gay, G Schett, AJ Hueber, S Frey Interleukin-36 receptor mediates the crosstalk between plasma cells and synovial fibroblasts Eur. J. Immunol., 2017-09-22;0(0):. 2017-09-22 [PMID: 28857172] (Western Blot, Mouse)
• IL-36 Induces Bisphosphonate-Related Osteonecrosis of the Jaw-Like Lesions in Mice by Inhibiting TGF-?-Mediated Collagen Expression J Bone Miner Res, 2016-10-12;0(0):. 10/12/2016 [PMID: 27567012]
• Milora K, Fu H, Dubaz O, Jensen L Unprocessed Interleukin-36alpha Regulates Psoriasis-Like Skin Inflammation in Cooperation With Interleukin-1. J Invest Dermatol, 2015-07-23;135(12):2992-3000. 7/23/2015 [PMID: 26203636]
• Johnston A, Xing X, Guzman AM, Riblett M, Loyd CM, Ward NL, Wohn C, Prens EP, Wang F, Maier LE, Kang S, Voorhees JJ, Elder JT, Gudjonsson JE IL-1F5, -F6, -F8, and -F9: A Novel IL-1 Family Signaling System That Is Active in Psoriasis and Promotes Keratinocyte Antimicrobial Peptide Expression. J. Immunol., 2011-01-17;186(4):2613-22. 2011-01-17 [PMID: 21242515] (IHC-P, Mouse)
• Martin U, Scholler J, Gurgel J, Renshaw B, Sims JE, Gabel CA Externalization of the leaderless cytokine IL-1F6 occurs in response to lipopolysaccharide/ATP activation of transduced bone marrow macrophages. J. Immunol., 2009-08-28;183(6):4021-30. 2009-08-28 [PMID: 19717513] (Western Blot, Mouse)

Bioinformatics

• Gene Symbol: IL36A
• Uniprot:
  • Q9JLA2()